Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: A randomized controlled study

Archives of Internal Medicine

Volumn 162, Issue 15, 2002, Pages 1729-1735

  Meyer, Guy ^a   Marjanovic, Zora ^a   Valcke, Judith ^a   Lorcerie, Bernard ^a   Gruel, Yves ^a   Solal Celigny, Philippe ^a   Le Maignan, Christine ^a   Extra, Jean Marc ^a   Cottu, Paul ^a   Farge, Dominique ^a  

^a Hop Europe en Georges Pompidou   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADULT; AGED; ARTICLE; BLEEDING; CANCER; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; THROMBOEMBOLISM; VEIN THROMBOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; EMBOLISM; ENDPOINT DETERMINATION; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; NEOPLASMS; RECURRENCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VENOUS THROMBOSIS; WARFARIN;

EID: 0037067889     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.162.15.1729     Document Type: Article

References (18)

1. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy
2. Should patients with venous thromboembolism and cancer be treated differently?
3. Prognosis of cancers associated with venous thromboembolism
4. Risk factors for bleeding during treatment of acute venous thromboembolism
5. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism
6. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism
7. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: A retrospective analysis
8. Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread
9. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis
10. Therapeutic and clinical course of deep vein thrombosis
11. The risk and efficacy of anticoagulant therapy in the treatment of thromboembolic complications in patients with primary malignant brain tumours
12. Cancer-related thromboembolic disease in patients with solid tumours: A retrospective analysis
13. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis
14. Bleeding and thromboembolism during anticoagulant therapy: A population-based study in Rochester, Minnesota
15. The efficacy and safety of oral anticoagulation in patients with cancer
16. Major bleeding after hospitalization for deep-venous thrombosis
17. Treatment of venous thromboembolism in cancer patients
18. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism